IP Library Granted Patent US 11,473,074
Granted Patent B2
US 11,473,074 · App. 15/939,231 · Granted Oct 18, 2022

Method of producing collagenase

Inventors: Christine A. Sheaffer (Doylestown, PA); Michael Berbaum (Pottstown, PA); John Hanna (East Norriton, PA); Jason Dziadosz (Quakertown, PA); Daniel Shanafelt (Red Hill, PA)
Assignee: Endo Global Aesthetics Limited
C12N9/52C12Y304/24003A61K31/00A61K38/00G01N33/56911
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,473,074
App. No.
15/939,231
Granted
Oct 18, 2022
Kind
B2
Abstract

The present invention relates to the fields of collagenase production and collagenase products, and particularly to improving the reproducibility, purity, and stability of collagenase I and collagenase II compositions, where the compositions are pure to at least 95% by area as measured by reverse phase high pressure liquid chromatography (RP-HPLC) and essentially free of neutral protease.

Claims (9)

1. An isolated and purified collagenase I and collagenase II composition obtained from Clostridium histolyticum , wherein the collagenase I and collagenase II have a mass ratio of about 1 to 1, and the composition is at least 95% by area pure as determined by reverse phase high performance liquid chromatography, wherein the composition is essentially free of delta toxin, and wherein the composition is made by a process comprising the steps of:

a. fermenting Clostridium histolyticum;

b. harvesting a crude fermentation comprising collagenase I and collagenase II; and

c. purifying collagenase I and collagenase II from the crude harvest via filtration and column chromatography comprising treating the collagenase I and collagenase II with an ammonium sulfate solution having a zinc level of less than about 80 ppm and a nickel level less than about 1.2 ppm.

2. The composition of claim 1 , wherein the process is performed in the presence of low levels of a metal selected from the group consisting of nickel, zinc, aluminum, arsenic, calcium, cadmium, chromium, copper, iron, magnesium, and lead.

3. The composition of claim 1 , wherein the nickel is present in an amount less than about 0.5 ppm.

4. The composition of claim 1 , wherein the nickel is present in an amount selected from the group consisting of less than about 0.9 ppm, less than about 0.8 ppm, less than about 0.7 ppm, less than about 0.6 ppm, less than about 0.5 ppm, less than about 0.4 ppm, less than about 0.3 ppm, less than about 0.2 ppm, less than about 0.1 ppm, less than about 0.09 ppm, less than about 0.08 ppm, less than about 0.07 ppm, less than about 0.06 ppm, less than about 0.05 ppm, less than about 0.04 ppm, less than about 0.03 ppm, less than about 0.02 ppm, and less than about 0.01 ppm.

5. The composition of claim 1 , wherein the zinc is present in an amount of less than about 1 ppm.

6. The composition of claim 1 , wherein the process further comprises a delta toxin elimination step comprising passing a collagenase filtrate through a separation column or filter.

Assignments (10)
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 068031/0059 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068031/0202 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ENDO GLOBAL AESTHETICS LIMITED; ENDO GLOBAL VENTURES; ENDO VENTURES BERMUDA LIMITED; ENDO VENTURES LIMITED; PALADIN LABS INC.
Reel/Frame 067221/0958 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ENDO GLOBAL AESTHETICS LIMITED; ENDO GLOBAL VENTURES; ENDO VENTURES BERMUDA LIMITED; ENDO VENTURES LIMITED; PALADIN LABS INC.
Reel/Frame 067216/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: ENDO VENTURES UNLIMITED COMPANY
To: OPERAND PHARMACEUTICALS III LIMITED
Reel/Frame 066732/0137 →
CHANGE OF NAME Recorded Mar 5, 2024
From: ENDO VENTURES LIMITED
To: ENDO VENTURES UNLIMITED COMPANY
Reel/Frame 066732/0396 →
CHANGE OF NAME Recorded Mar 5, 2024
From: OPERAND PHARMACEUTICALS III LIMITED
To: ENDO OPERATIONS LIMITED
Reel/Frame 066732/0413 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ENDO VENTURES LIMITED; ENDO GLOBAL VENTURES; PALADIN LABS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0893 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 26, 2020
From: ENDO GLOBAL VENTURES; ENDO VENTURES LIMITED; PALADIN LABS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 053548/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2018
From: SHEAFFER, CHRISTINE A.; BERBAUM, MICHAEL; HANNA, JOHN; DZIADOSZ, JASON; SHANAFELT, DANIEL
To: ENDO VENTURES LIMITED
Reel/Frame 046633/0862 →